Visualizing VEGF producing lesions in Von Hippel-Lindau disease - VHL image
- Conditions
- To determine if disease associated lesions in patients with VHLD can be visualized with 89Zr-bevacizumab PET scans.
- Registration Number
- EUCTR2009-011479-62-NL
- Lead Sponsor
- niversity Medical Center Groningen
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised-recruitment may be ongoing or finished
- Sex
- All
- Target Recruitment
- Not specified
•clinically or genetically proven VHLD
•at least 1 measurable, VHL associated lesion on MRI
•routine MRI of the CNS and upper abdomen = 4 weeks before inclusion
•age = 18 years
•written informed consent must be given according to good clinical practice (GCP), and local regulations
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
•pregnancy
•any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol, those conditions should be discussed with the patient before registration in the trial
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method